The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets thought to protect tumours from attack by the immune system.
Copyright © 2024 | WordPress Theme by MH Themes